WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009063215) USE OF CRTH2 ANTAGONIST COMPOUNDS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/063215    International Application No.:    PCT/GB2008/003843
Publication Date: 22.05.2009 International Filing Date: 13.11.2008
IPC:
A61K 31/405 (2006.01), A61K 31/4439 (2006.01), A61K 31/4709 (2006.01), A61K 45/06 (2006.01), A61P 37/08 (2006.01), A61P 11/06 (2006.01), A61P 27/14 (2006.01)
Applicants: OXAGEN LIMITED [GB/GB]; 91 Milton Park, Abingdon, Oxon OX14 4RY (GB) (For All Designated States Except US).
HUNTER, Michael, George [GB/GB]; (GB) (For US Only).
PETTIPHER, Eric, Roy [GB/GB]; (GB) (For US Only).
PERKINS, Colin, Michael [GB/GB]; (GB) (For US Only).
PAYTON, Mark, Anthony [GB/GB]; (GB) (For US Only).
XUE, Luzheng [CN/GB]; (GB) (For US Only)
Inventors: HUNTER, Michael, George; (GB).
PETTIPHER, Eric, Roy; (GB).
PERKINS, Colin, Michael; (GB).
PAYTON, Mark, Anthony; (GB).
XUE, Luzheng; (GB)
Agent: ROBERTS, Alison, Christine; Kilburn & Strode LLP, 20 Red Lion Street, London WC1R 4PJ (GB)
Priority Data:
0722216.9 13.11.2007 GB
Title (EN) USE OF CRTH2 ANTAGONIST COMPOUNDS
(FR) UTILISATION DE COMPOSÉS ANTAGONISTES DE CRTH2
Abstract: front page image
(EN)The invention relates to compounds of general formula (I): wherein R1, R2, R3, R4 and R5 are as defined herein for desensitising the immune system of a subject to allergens, thus preventing or reducing the symptoms of allergic conditions such as allergic asthma, allergic rhinitis or atopic dermatitis.
(FR)L'invention concerne des composés représentés par la formule générale (I), dans laquelle R1, R2, R3, R4 et R5 sont tels que définis dans le descriptif et qui servent à désensibiliser le système immunitaire d'un sujet à des allergènes, afin de prévenir ou de réduire les symptômes de pathologies allergiques telles que l'asthme allergique, la rhinite allergique ou la dermatite atopique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)